METHOD FOR DETERMINING THE RISK OF OCCURRENCE OF ALZHEIMER'S DISEASE

FIELD OF THE INVENTION

The present invention relates to a method for determining the risk of occurrence of Alzheimer's disease.

Technical Background

AD is a neurological disorder primarily affecting the elderly that manifests by memory disorders, cognitive decline and loss of autonomy. The incidence of AD is rising rapidly, raising fears that a large fraction of an increasingly elderly population will ultimately be affected. The need for effective preventive and therapeutic measures has motivated extensive research into the disease pathogenesis.

The pathology of AD is characterized by neuronal loss leading to atrophy and to diminution of the cerebral metabolism that initially has limited dispersion but which subsequently spreads to the entire brain. Two principal types of neuropathologic lesions are observed: (i) neurofibrillary degeneration resulting from the intraneuronal accumulation of hyperphosphorylated Tau proteins; (ii) amyloid deposits resulting from the extracellular accumulation of amyloid plaques, principally composed of amyloid β (Aβ) peptide. Currently, the processes leading to formation of these lesions and their dual association with AD are not adequately understood.

Genetic studies have provided significant insights into the molecular basis of AD. Rare hereditary early-onset forms of the disease have been linked to mutations in three different genes: the amyloid precursor protein (APP) gene on chromosome 21, the presenilin 1 (PS1) gene on chromosome 14 and the presenilin 2 (PS2) gene on chromosome 1. In vitro and in vivo studies have shown that pathogenic mutations in APP, PS1 and PS2 favour Aβ peptide production, particularly Aβn-42(43). These latter observations support the amyloid cascade hypothesis, namely of overproduction of the Aβ peptides, which would provoke neurofibrillary degeneration and finally neuronal death. These mutations, however, explain less than 1% of all AD cases whereas the vast majority of AD cases (especially late-onset forms) have other more complex genetic determinants.

Genetic studies have led to the identification of the ε4 allele of the apolipoprotein E gene (APOE) as one of the susceptibility loci for late-onset AD (Farrer et al. (1997) JAMA 278:1349-1356). Biological investigations have shown that APOE is likely to play a significant role in the fibrillogenesis and in clearance of Aβ peptide. Twin studies suggest that genes may contribute in more than 60% of AD susceptibility whereas APOE may account as much as 50% of this genetic susceptibility (Ashford & Mortimer (2002) J. Alzheimer Dis. 4:169-177).

More than 550 other genes have been proposed as candidates for involvement in the disease, but thus far none of these has been confirmed to have a role in pathogenesis (Bertram et al. (2007) Nat. Genet. 39:17-23).

Accordingly, it is an object of the present invention to provide alternative genetic risk factors to APOE for Alzheimer's disease.

DESCRIPTION OF THE INVENTION

The present invention arises from the unexpected finding, by the present inventors, that variants of the apolipoprotein J gene (APOJ) and of the complement component receptor 1 gene (CR1) were risk factors for the onset of Alzheimer's disease.

The present invention thus relates to an in vitro method for determining that an individual is at risk of developing Alzheimer's disease, which comprises:

determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR1);

deducing that if the individual harbours at least one variant allele of the APOJ and/or CR1 gene then the individual is at risk of developing Alzheimer's disease.

In an embodiment, the invention further comprises further determining whether the individual presents at least one other risk factor for Alzheimer's disease and deducing that the individual is at risk of developing Alzheimer's disease if said individual harbours at least one variant allele of the APOJ and/or the CR1 gene and presents said at least one other risk factor.

As intended herein the above-defined individual is preferably a human.

“Alzheimer's disease” is well known to one of skill in the art and is notably characterized by an abnormal accumulation of plaques resulting from the aggregation of the β-amyloid peptide.

As intended herein, the expression “the individual is at risk of developing Azheimer's disease” notably means that the individual is predisposed to develop the Alzheimer's disease or that the individual presents an increased risk of developing Alzheimer's disease with respect to a general population of individuals or to a population of individuals which do not harbour the above-defined at least one variant allele of the APOJ and/or CR1 gene.

The “apolipoprotein J gene (APOJ)”, is also known, inter alia, as the clusterin (CLU) gene. APOJ sensu stricto is localized on chromosome 8 in the cytogenetic band 8p21-p12 and in particular spans bases starting from position 27,455,514 bp from pter to position 27,466,601 bp from pter on the plus strand of chromosome 8 as defined by the build 37 of the human genome released on February 2009. The man skilled in the art can readily define other positions for the APOJ gene depending on the chosen count origin such as the centromere of the chromosome for instance. By way of example, the APOJ coding sequence (mRNA) is represented by the NCBI Reference Sequence NM_—001831 (SEQ ID NO: 1) and the apolipoprotein J is represented by the NCBI Reference Sequence NP_—001822 (SEQ ID NO: 2).

The “complement component receptor 1 gene (CR1)”, or complement component (3b/4b) receptor 1 gene, sensu stricto is localized on chromosome 1 in the cytogenetic band 1q32 and in particular spans bases starting from position 207,669,473 bp from pter to position 207,815,109 bp from pter on the plus strand of chromosome 1 as defined by the build 37 of the human genome released on February 2009. The man skilled in the art can readily define other positions for the CR1 gene depending on the chosen count origin such as the centromere of the chromosome for instance. By way of example, the CR1 coding sequence (mRNA) is represented by the NCBI Reference Sequence NM_—000651 (SEQ ID NO: 3) and the CR1 protein is represented by the NCBI Reference Sequence NP_—000642 (SEQ ID NO: 4).

As will be clear to one of skill in the art, the expression “determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR1)” preferably refers to determining the presence or absence of at least one variation, such as a substitution (in particular a single nucleotide polymorphism (SNP)), a deletion (del) or an insertion (ins), at a site of polymorphism, i.e. a site of the genome which sequence is not identical in all individuals, comprised in said susceptibility gene. It is then deduced that the individual is at risk of developing Alzheimer's disease if the variation is present in the individual.

As intended herein the “susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR1)” also encompasses sequences directly upstream and downstream of the APOJ and CR1 gene sensu stricto, and in particular spans bases starting from position 27,400,000 bp from pter to position 27,520,000 bp from pter on the plus strand of chromosome 8 as defined by the build 37 of the human genome released on February 2009 for APOJ and bases starting from position 207,615,000 bp from pter to position 207,870,000 bp from pter on the plus strand of chromosome 1 as defined by the build 37 of the human genome released on February 2009 for CR1.

Where the susceptibility gene is APOJ, the invention preferably comprises:

determining the presence or absence of at least one variation selected from the group consisting of:

a C for the C/T single nucleotide polymorphism (SNP) rs2279590;

a C for the C/T SNP rs11136000; and

a G for the C/G SNP rs9331888; in the individual;

deducing that the individual is at risk of developing Alzheimer's disease if said at least one variation is present.

Still preferably, when the susceptibility gene is APOJ, the invention comprises:

determining the presence or absence of at least one variation selected from the group consisting of:

a T for the C/T SNP rs10091215;

an A for the T/A SNP rs1073742;

an A for the G/A SNP rs1073743;

a T for the C/T SNP rs10780145;

an A for the A/G SNP rs10866859;

a T for the C/T SNP rs11136000;

a T for the C/T SNP rs11787077;

a T for the C/T SNP rs1532276;

a T for the C/T SNP rs1532277;

a T for the C/T SNP rs1532278;

a G for the A/G SNP rs17057419;

an A for the A/G SNP rs17466684;

a T for the C/T SNP rs1982229;

a C for the G/C SNP rs2070926;

a T for the T/C SNP rs2279590;

a T for the T/C SNP rs2279591;

a C for the C/T SNP rs2582367;

a G for the C/G SNP rs28558661;

a C for the C/G SNP rs35810222;

an A for the A/G SNP rs4236673;

a C for the C/T SNP rs4352801;

a G for the C/G SNP rs4732728;

an A for the A/C SNP rs4732729;

an A for the A/G SNP rs4732732;

a C for the C/T SNP rs484377;

a C for the G/C SNP rs485902;

a T for the G/T SNP rs492638;

a G for the G/T SNP rs495150;

a T for the G/T SNP rs504038;

a C for the C/T SNP rs507341;

a G for the C/G SNP rs518317;

an A for the A/G SNP rs520186;

a G for the A/G SNP rs536332;

a G for the A/G SNP rs538181;

a T for the A/T SNP rs569205;

an A for the A/G SNP rs576748;

a T for the C/T SNP rs6983452;

a C for the C/T SNP rs7828131;

an A for the G/A SNP rs7982;

a C for the A/C SNP rs867230;

a G for the A/G SNP rs9314349;

a C for the T/C SNP rs9331896;

a T for the T/C SNP rs9331908;

an A for the SNP located at nucleotide position 27496798 of human chromosome 8;

a T for the SNP located at nucleotide position 27498182 of human chromosome 8;

a T for the SNP located at nucleotide position 27533395 of human chromosome 8;

a G for the SNP located at nucleotide position 27542063 of human chromosome 8;

a G for the SNP located at nucleotide position 27542086 of human chromosome 8;

an A for the SNP located at nucleotide position 27542087 of human chromosome 8; and

a T for the SNP located at nucleotide position 27542353 of human chromosome 8, in the individual;

deducing that the individual is at risk of developing Alzheimer's disease if said at least one variation is present.

Still preferably, when the susceptibility gene is APOJ, the invention comprises:

determining the presence or absence of at least one variation selected from the group consisting of:

a T for the C/T SNP rs10091215;

an A for the T/A SNP rs1073742;

an A for the G/A SNP rs1073743;

a T for the C/T SNP rs10780145;

an A for the A/G SNP rs10866859;

a T for the C/T SNP rs11136000;

a T for the C/T SNP rs11787077;

a T for the C/T SNP rs1532276;

a T for the C/T SNP rs1532277;

a T for the C/T SNP rs1532278;

a G for the A/G SNP rs17057419;

an A for the A/G SNP rs17466684;

a T for the C/T SNP rs1982229;

a C for the G/C SNP rs2070926;

a T for the T/C SNP rs2279590;

a T for the T/C SNP rs2279591;

a C for the C/T SNP rs2582367;

a G for the C/G SNP rs28558661;

a C for the C/G SNP rs35810222;

an A for the A/G SNP rs4236673;

a C for the C/T SNP rs4352801;

a G for the C/G SNP rs4732728;

an A for the A/C SNP rs4732729;

an A for the A/G SNP rs4732732;

a C for the C/T SNP rs484377;

a C for the G/C SNP rs485902;

a T for the G/T SNP rs492638;

a G for the G/T SNP rs495150;

a T for the G/T SNP rs504038;

a C for the C/T SNP rs507341;

a G for the C/G SNP rs518317;

an A for the A/G SNP rs520186;

a G for the A/G SNP rs536332;

a G for the A/G SNP rs538181;

a T for the A/T SNP rs569205;

an A for the A/G SNP rs576748;

a T for the C/T SNP rs6983452;

a C for the C/T SNP rs7828131;

an A for the G/A SNP rs7982;

a C for the A/C SNP rs867230;

a G for the A/G SNP rs9314349;

a C for the T/C SNP rs9331896; and

a T for the T/C SNP rs9331908; in the individual;

deducing that the individual is at risk of developing Alzheimer's disease if said at least one variation is present.

More preferably, it is deduced that the individual is at risk of developing Alzheimer's disease if it is determined that the individual presents a C for the C/T SNP, rs2279590, a C for the C/T SNP rs11136000, and a C or a G, preferably a G, for the C/G SNP rs9331888.

Still preferably, it is deduced that the individual is at risk of developing Alzheimer's disease if it is determined that the individual presents a T for the C/T SNP rs10091215, an A for the T/A SNP rs1073742, an A for the G/A SNP rs1073743, a T for the C/T SNP rs10780145, an A for the A/G SNP rs10866859, a T for the C/T SNP rs11136000, a T for the C/T SNP rs11787077, a T for the C/T SNP rs1532276, a T for the C/T SNP rs1532277, a T for the C/T SNP rs1532278, a G for the A/G SNP rs17057419, an A for the A/G SNP rs17466684, a T for the C/T SNP rs1982229, a C for the G/C SNP rs2070926, a T for the T/C SNP rs2279590, a T for the T/C SNP rs2279591, a C for the C/T SNP rs2582367, a G for the C/G SNP rs28558661, a C for the C/G SNP rs35810222, an A for the A/G SNP rs4236673, a C for the C/T SNP rs4352801, a G for the C/G SNP rs4732728, an A for the A/C SNP rs4732729, an A for the A/G SNP rs4732732, a C for the C/T SNP rs484377, a C for the G/C SNP rs485902, a T for the G/T SNP rs492638, a G for the G/T SNP rs495150, a T for the G/T SNP rs504038, a C for the C/T SNP rs507341, a G for the C/G SNP rs518317, an A for the A/G SNP rs520186, a G for the A/G SNP rs536332, a G for the A/G SNP rs538181, a T for the NT SNP rs569205, an A for the A/G SNP rs576748, a T for the C/T SNP rs6983452, a C for the C/T SNP rs7828131, an A for the G/A SNP rs7982, a C for the A/C SNP rs867230, a G for the A/G SNP rs9314349, a C for the T/C SNP rs9331896, a T for the T/C SNP rs9331908, an A for the SNP located at nucleotide position 27496798 of human chromosome 8, a T for the SNP located at nucleotide position 27498182 of human chromosome 8, a T for the SNP located at nucleotide position 27533395 of human chromosome 8, a G for the SNP located at nucleotide position 27542063 of human chromosome 8, a G for the SNP located at nucleotide position 27542086 of human chromosome 8, an A for the SNP located at nucleotide position 27542087 of human chromosome 8 and a T for the SNP located at nucleotide position 27542353 of human chromosome 8.

Besides, where the susceptibility gene is CR1, the invention preferably comprises:

determining the presence or absence of at least one variation selected from the group consisting of:

an A for the A/G SNP rs6656401; and

an A for the A/G SNP rs3818361; in the individual;

deducing that the individual is at risk of developing Alzheimer's disease if said at least one variation is present.

Still preferably, where the susceptibility gene is CR1, the invention comprises:

determining the presence or absence of at least one variation selected from the group consisting of:

a C for the C/T SNP rs10779335;

a T for the G/T SNP rs10779336;

a T for the C/T SNP rs10863336;

an A for the A/T SNP rs10863417;

a C for the C/G SNP rs10863418;

an A for the A/C SNP rs10863420;

an A for the A/G SNP rs11576522;

an A for the A/G SNP rs11579070;

a T for the −/C/T SNP rs11803366;

a T for the C/T SNP rs11803956;

an A for the A/T SNP rs12028134;

an A for the A/G SNP rs12031281;

a G for the A/G SNP rs12032780;

a G for the A/G SNP rs12034383;

a C for the A/C SNP rs12036785;

a T for the G/T SNP rs12037841;

a G for the A/G SNP rs12038371;

a C for the A/C SNP rs12041437;

an A for the C/A SNP rs1408077;

a T for the T/C SNP rs1408078;

a T for the C/T SNP rs17186848;

a G for the A/G SNP rs17258982;

an A for the A/G SNP rs1752684;

a C for the C/A SNP rs1830763;

an A for the G/A SNP rs2093760;

an A for the G/A SNP rs2093761;

a C for the C/T SNP rs2182911;

a T for the A/T SNP rs2182912;

an A for the A/G SNP rs2182913;

a C for the C/T SNP rs2274566;

an A for the T/G/A SNP rs2296160;

a T for the C/T SNP rs3737002;

an A for the A/G SNP rs3738469;

an A for the G/A SNP rs3818361;

a T for the C/T SNP rs3849266;

an A for the A/G SNP rs3886100;

a T for the C/T SNP rs4266886;

a C for the −/C/T SNP rs4274065;

a C for the −/C/T SNP rs4310446;

a T for the C/T SNP rs4525038;

an A for the A/C SNP rs4562624;

a C for the C/T SNP rs4618970;

a C for the C/T SNP rs4618971;

a C for the C/G SNP rs4844383;

a C for the −/A/C/T SNP rs4844597;

an A for the A/C/G SNP rs4844600;

an A for the A/C SNP rs4844610;

a C for the A/C SNP rs6540433;

an A for the A/G SNP rs6656401;

a T for the C/T SNP rs6661489;

a G for the A/C/G SNP rs6661764;

an A for the A/G SNP rs6686325;

a C for the C/T SNP rs6690215;

a G for the −/A/G SNP rs6697005;

an A for the A/G SNP rs6701713;

a T for the C/T SNP rs679515;

a T for the C/T SNP rs7515905;

a G for the A/G SNP rs7519119;

a G for the C/G SNP rs7519408;

a C for the C/G SNP rs7525160;

a G for the A/G SNP rs7525170;

an A for the −/A/G SNP rs7533520;

a C for the A/C SNP rs7542544;

a G for the A/G SNP rs9429779;

a G for the C/G SNP rs9429780;

a G for the G/T SNP rs9429781;

a G for the A/G SNP rs9429784;

a T for the C/T SNP rs9429940;

a T for the A/T SNP rs9429941;

a C for the C/T SNP rs9429942;

a T for the −/C/T SNP rs9429945;

a C for the SNP located at nucleotide position 205717682 of human chromosome 1;

a T for the SNP located at nucleotide position 205734924 of human chromosome 1;

a G for the SNP located at nucleotide position 205762211 of human chromosome 1;

a G for the SNP located at nucleotide position 205796833 of human chromosome 1;

a T for the SNP located at nucleotide position 205857663 of human chromosome 1;

a G for the SNP located at nucleotide position 205862688 of human chromosome 1;

a T for the SNP located at nucleotide position 205867485 of human chromosome 1;

an A for the SNP located at nucleotide position 205877247 of human chromosome 1;

a T for the SNP located at nucleotide position 205878796 of human chromosome 1;

a T for the SNP located at nucleotide position 205879028 of human chromosome 1;

an A for the SNP located at nucleotide position 205886998 of human chromosome 1;

an A for the SNP located at nucleotide position 205888190 of human chromosome 1;

a G for the SNP located at nucleotide position 205892038 of human chromosome 1; and

a T for the SNP located at nucleotide position 205895594 of human chromosome 1, in the individual;

deducing that the individual is at risk of developing Alzheimer's disease if said at least one variation is present.

Still preferably, where the susceptibility gene is CR1, the invention comprises:

determining the presence or absence of at least one variation selected from the group consisting of:

- a C for the C/T SNP rs10779335;

a T for the G/T SNP rs10779336;

a T for the C/T SNP rs10863336;

an A for the A/T SNP rs10863417;

a C for the C/G SNP rs10863418;

an A for the A/C SNP rs10863420;

an A for the A/G SNP rs11576522;

an A for the A/G SNP rs11579070;

a T for the −/C/T SNP rs11803366;

a T for the C/T SNP rs11803956;

an A for the A/T SNP rs12028134;

an A for the A/G SNP rs12031281;

a G for the A/G SNP rs12032780;

a G for the A/G SNP rs12034383;

a C for the A/C SNP rs12036785;

a T for the G/T SNP rs12037841;

a G for the A/G SNP rs12038371;

a C for the A/C SNP rs12041437;

an A for the C/A SNP rs1408077;

a T for the T/C SNP rs1408078;

a T for the C/T SNP rs17186848;

a G for the A/G SNP rs17258982;

an A for the A/G SNP rs1752684;

a C for the C/A SNP rs1830763;

an A for the G/A SNP rs2093760;

an A for the G/A SNP rs2093761;

a C for the C/T SNP rs2182911;

a T for the A/T SNP rs2182912;

an A for the A/G SNP rs2182913;

a C for the C/T SNP rs2274566;

an A for the T/G/A SNP rs2296160;

a T for the C/T SNP rs3737002;

an A for the A/G SNP rs3738469;

an A for the G/A SNP rs3818361;

a T for the C/T SNP rs3849266;

an A for the A/G SNP rs3886100;

a T for the C/T SNP rs4266886;

- a C for the −/C/T SNP rs4274065;

a C for the −/C/T SNP rs4310446;

a T for the C/T SNP rs4525038;

an A for the A/C SNP rs4562624;

a C for the C/T SNP rs4618970;

a C for the C/T SNP rs4618971;

a C for the C/G SNP rs4844383;

a C for the −/A/C/T SNP rs4844597;

an A for the A/C/G SNP rs4844600;

an A for the A/C SNP rs4844610;

a C for the A/C SNP rs6540433;

an A for the A/G SNP rs6656401;

a T for the C/T SNP rs6661489;

a G for the A/C/G SNP rs6661764;

an A for the A/G SNP rs6686325;

a C for the C/T SNP rs6690215;

a G for the −/A/G SNP rs6697005;

an A for the A/G SNP rs6701713;

a T for the C/T SNP rs679515;

a T for the C/T SNP rs7515905;

a G for the A/G SNP rs7519119;

a G for the C/G SNP rs7519408;

a C for the C/G SNP rs7525160;

a G for the A/G SNP rs7525170;

an A for the −/A/G SNP rs7533520;

a C for the A/C SNP rs7542544;

a G for the A/G SNP rs9429779;

a G for the C/G SNP rs9429780;

a G for the G/T SNP rs9429781;

a G for the A/G SNP rs9429784;

a T for the C/T SNP rs9429940;

a T for the A/T SNP rs9429941;

a C for the C/T SNP rs9429942; and

a T for the −/C/T SNP rs9429945; in the individual;

deducing that the individual is at risk of developing Alzheimer's disease if said at least one variation is present.

More preferably, it is deduced that the individual is at risk of developing Alzheimer's disease if it is determined that the individual presents an A for the A/G SNP rs6656401, and a G or an A, preferably an A, for the A/G SNP rs3818361.

Still preferably, it is deduced that the individual is at risk of developing Alzheimer's disease if it is determined that the individual presents a C for the C/T SNP rs10779335, a T for the G/T SNP rs10779336, a T for the C/T SNP rs10863336, an A for the NT SNP rs10863417, a C for the C/G SNP rs10863418, an A for the A/C SNP rs10863420, an A for the A/G SNP rs11576522, an A for the A/G SNP rs11579070, a T for the −/C/T SNP rs11803366, a T for the C/T SNP rs11803956, an A for the NT SNP rs12028134, an A for the A/G SNP rs12031281, a G for the A/G SNP rs12032780, a G for the A/G SNP rs12034383, a C for the A/C SNP rs12036785, a T for the G/T SNP rs12037841, a G for the A/G SNP rs12038371, a C for the A/C SNP rs12041437, an A for the C/A SNP rs1408077, a T for the T/C SNP rs1408078, a T for the C/T SNP rs17186848, a G for the A/G SNP rs17258982, an A for the A/G SNP rs1752684, a C for the C/A SNP rs1830763, an A for the G/A SNP rs2093760, an A for the G/A SNP rs2093761, a C for the C/T SNP rs2182911, a T for the NT SNP rs2182912, an A for the A/G SNP rs2182913, a C for the C/T SNP rs2274566, an A for the T/G/A SNP rs2296160, a T for the C/T SNP rs3737002, an A for the A/G SNP rs3738469, an A for the G/A SNP rs3818361, a T for the C/T SNP rs3849266, an A for the A/G SNP rs3886100, a T for the C/T SNP rs4266886, a C for the −/C/T SNP rs4274065, a C for the −/C/T SNP rs4310446, a T for the C/T SNP rs4525038, an A for the A/C SNP rs4562624, a C for the C/T SNP rs4618970, a C for the C/T SNP rs4618971, a C for the C/G SNP rs4844383, a C for the −/A/C/T SNP rs4844597, an A for the A/C/G SNP rs4844600, an A for the A/C SNP rs4844610, a C for the A/C SNP rs6540433, an A for the A/G SNP rs6656401, a T for the C/T SNP rs6661489, a G for the A/C/G SNP rs6661764, an

A for the A/G SNP rs6686325, a C for the C/T SNP rs6690215, a G for the −/A/G SNP rs6697005, an A for the A/G SNP rs6701713, a T for the C/T SNP rs679515, a T for the C/T SNP rs7515905, a G for the A/G SNP rs7519119, a G for the C/G SNP rs7519408, a C for the C/G SNP rs7525160, a G for the A/G SNP rs7525170, an A for the −/A/G SNP rs7533520, a C for the A/C SNP rs7542544, a G for the A/G SNP rs9429779, a G for the C/G SNP rs9429780, a G for the G/T SNP rs9429781, a G for the A/G SNP rs9429784, a T for the C/T SNP rs9429940, a T for the NT SNP rs9429941, a C for the C/T SNP rs9429942, a T for the −/C/T SNP rs9429945, a C for the SNP located at nucleotide position 205717682 of human chromosome 1, a T for the SNP located at nucleotide position 205734924 of human chromosome 1, a G for the SNP located at nucleotide position 205762211 of human chromosome 1, a G for the SNP located at nucleotide position 205796833 of human chromosome 1, a T for the SNP located at nucleotide position 205857663 of human chromosome 1, a G for the SNP located at nucleotide position 205862688 of human chromosome 1, a T for the SNP located at nucleotide position 205867485 of human chromosome 1, an A for the SNP located at nucleotide position 205877247 of human chromosome 1, a T for the SNP located at nucleotide position 205878796 of human chromosome 1, a T for the SNP located at nucleotide position 205879028 of human chromosome 1, an A for the SNP located at nucleotide position 205886998 of human chromosome 1, an A for the SNP located at nucleotide position 205888190 of human chromosome 1, a G for the SNP located at nucleotide position 205892038 of human chromosome 1 and a T for the SNP located at nucleotide position 205895594 of human chromosome 1.

The above-defined variations are well known to one of skill in the art and are notably described in the NCBI database dbSNP (www.ncbi.nlm.nih.gov/SNP/). When the above-defined variations are defined by the location of the SNP on a human chromosome, said location corresponds to the one described in the databases HG18/NCBI 36.3. It is thus within the general knowledge of the skilled person to obtain the sequences of the above-defined variations from their locations on the chromosomes.

As will be clear to one of skill in the art, a C/T, C/G or A/G SNP read on a first nucleic acid strand is respectively identical to a A/G, C/G or C/T SNP read on the complementary strand to said first nucleic acid strand.

For the purpose of unambiguously identifying the above variations, the sequences flanking the above-defined variations are notably represented by the following sequences wherein the variation is shown between square brackets:

rs2279590:

(SEQ ID NO: 5)

CTTCTGATAAGGAAGTCCTCCTGCT[C/T]CTCCAAGGAAACCTAGAGA

GCTGACC

rs11136000:

(SEQ ID NO: 6)

CACCAAAGCCACACCAGCTATCAAAA[C/T]TCTCTAACGGGCCCTTGC

CACTTGA

rs9331888:

(SEQ ID NO: 7)

AGAGCAAGAGGACTCATCCTTCCAAA[C/G]GGACTTTCTCTGGGAAGC

CTGCTCC

rs6656401:

(SEQ ID NO: 8)

ATTTCCTTCTCTGTCTCCATCTTCTC[A/G]TCGCCTTCTCCTCTGTGT

GTGTCCT

rs3818361:

(SEQ ID NO: 9)

AGCCCTCTGGTAAGCATAAGATATA[A/G]CAAAGGAAATTGCCCCATA

TCTAACA

rs10091215:

(SEQ ID NO: 10)

TCACCGTGGTCTCGATATCCTGACCT[C/T]GTGATCCACTCGCCTCGG

CCTCCCA

rs1073742:

(SEQ ID NO: 11)

TCCAGCCTGGGCAACAGAGTGCGAC[T/A]CTGTCTCTAAAAAGAAAAA

AATAATT

rs1073743:

(SEQ ID NO: 12)

TTGGCTCATGCCTGTAATCACAGCA[G/A]TCTGGGAGGCTGAGGCAAG

AGGATCA

rs10780145:

(SEQ ID NO: 13)

AGCTGATGCCTATATATTGCTTGCCA[C/T]GTGCCTGACCATTTTAAA

CACCTTC

rs10866859:

(SEQ ID NO: 14)

CAGTAGCTGATGCCTATATATTGCTT[A/G]CCACGTGCCTGACCATTT

TAAACAC

rs11787077:

(SEQ ID NO: 15)

CCACACCCCAGAGTTAGGTGAGGTCT[C/T]GTCCTGCTCCATCATCCC

CTGTCC

rs1532276:

(SEQ ID NO: 16)

CTGTCTGGGCCCCTGCCGCCACCCCA[C/T]CCAGAGCCTGCTTGGAAC

TAGCATG

rs1532277:

(SEQ ID NO: 17)

CATCCAGAGCCTGCTTGGAACTAGCA[C/T]GTGATCAGGGCTTAGAAA

CATCTAT

rs1532278:

(SEQ ID NO: 18)

GCAAATGAACCTTCCCTGCTTCTTAA[C/T]TGCAGCCTCAGCATCAGC

TGACACA

rs17057419:

(SEQ ID NO: 19)

GTCTCCTCTGGTGGAGGAAAGCTCTA[A/G]TAGGACCCTGCAGTGCCA

GGTCCGC

rs17466684:

(SEQ ID NO: 20)

AGAACTACTGGATACTTCCTGGGTTT[A/G]CCACTATCCTATTTTCTA

GTGGGGC

rs1982229:

(SEQ ID NO: 21)

ATTCTGGACCTCATCTCTCTTGAAAC[C/T]CTTGGCCCAGCCCTGGAC

TAGCCAA

rs2070926:

(SEQ ID NO: 22)

CACGCAGAGCCTGAACCAGGGGCCT[G/C]GGAGCTGAGGCTCAGAGTG

GGCCCAG

rs2279591:

(SEQ ID NO: 23)

CTGCTCCCCCTTTGCCACAAGAGTC[T/C]TAGAAGCCAGACACTAAGG

GCTCAGG

rs2582367:

(SEQ ID NO: 24)

TACAGGCATGAGCCACCACTCCCAGC[C/T]GTAACTACATAGCTTAAA

AACAATA

rs28558661:

(SEQ ID NO: 25)

ACAGAGTGAGACTCTGTCTCGGGGGG[C/G]GGGGGGGGGGGGAAGCAG

CAACCAA

rs35810222:

(SEQ ID NO: 26)

GGCCAGGCTGGTCTTGAACTCCTGAC[C/G]TCAAGTAATCTGCCCGCC

TCGGCCT

rs4236673:

(SEQ ID NO: 27)

AGGAATCCCCTGACAAAGAAAAAGAT[A/G]CTTAAAAATATTTGAAAC

AGTATTA

rs4352801:

(SEQ ID NO: 28)

TTCCTCTGGTTCCCACACAGCGAGAA[C/T]GTCAGTGCCATCCACCAG

GACCACA

rs4732728:

(SEQ ID NO: 29)

TGGCCAGGCTGGTCCCCAAGACACCA[C/G]AGAGCATCTGCCTAGAAA

GAGGCAA

rs4732729:

(SEQ ID NO: 30)

GCGCTTGGCGCTTGGGAACAGAATCA[A/C]CGGGGAGTCCCAGGGGGA

TGACTTT

rs4732732:

(SEQ ID NO: 31)

CAAAAATTAGCTGGGCATGGTGGCAC[A/G]CGCCTGCAGTCCCAGCTA

CTCGGGA

rs484377:

(SEQ ID NO: 32)

TTTTGGTTTTGTTTTGTTTTTTAATA[C/T]GGAGCTCATCCCGTCGCC

CAGCCTG

rs485902:

(SEQ ID NO: 33)

ACTGGGCAAGTGCCCCAAGAGGTGG[G/C]CTTTCAATGTCGGAGAGCC

AAAAAAC

rs492638:

(SEQ ID NO: 34)

AAAGTGACCCTTTGTGTGTTGTCAGT[G/T]TTTTTCCAACCAGATTAT

CATTTTT

rs495150:

(SEQ ID NO: 35)

AAGGTTCATAGGTATTAACTTGACCC[G/T]ATTAAGCCCTCTTTGAAG

ATTTATC

rs504038:

(SEQ ID NO: 36)

CAGCTACTCAGGAAGCTGAGATGGAG[G/T]ATCGCTTGAGCCCAGGAG

GTCAAGG

rs507341:

(SEQ ID NO: 37)

TGAAGACAGAGATGTTTCCAGTCCTA[C/T]TTGCAGTAACCTAAAATT

GCAGGAC

rs518317:

(SEQ ID NO: 38)

AAATATTATTTTATTTATTTATTTTT[C/G]AGACAGGGTCTCACTCTG

TCACCCA

rs520186:

(SEQ ID NO: 39)

GTTTTCAACTATTTATTTTTAAATAA[A/G]ATTTCCCCTCTGTCACTT

GTCTATC

rs536332:

(SEQ ID NO: 40)

CTGCATAGTATTCCATGGTGTATACC[A/G]TAGTATTCCATGGTGTAT

ATATACC

rs538181:

(SEQ ID NO: 41)

TTCTGAGTGATTTTCTCCGGACCTCC[A/G]TAAAGTCCAGAAACATTC

ACTCCAT

rs569205:

(SEQ ID NO: 42)

TGTATTTCACTCCAGAGTTGCTTTAC[A/T]GTGACCTTTAGCTCCAAT

TATTAGG

rs576748:

(SEQ ID NO: 43)

GGAAGAGATCAATTTCCCTGAGCACT[A/G]AGGGCTGATACTATGTTC

TCAGGAG

rs6983452:

(SEQ ID NO: 44)

CTTTATAACAGCATTATTTACAATAG[C/T]CAAATGTCTTATCAAGAC

AAATGGA

rs7828131:

(SEQ ID NO: 45)

CAGGGGAGGGGGACTACAGGTGGCAC[C/T]AGAGGGACCCCACTAAAC

AAACCAT

rs7982:

(SEQ ID NO: 46)

TTGGCGGGTGCTGGAAGGCCGGGCT[G/A]TGGAAGTGGATGTCCATGG

CCTGCTG

rs867230:

(SEQ ID NO: 47)

CGATCATGTCAGACACTGAAAATACC[A/C]CCCTTAGGTCATGCATCC

GTCCCTC

rs9314349:

(SEQ ID NO: 48)

TTTCATATTCTAAGCAGATCATAGAC[A/G]TTGATTGGTTCAGGACTC

ACACACT

rs9331896:

(SEQ ID NO: 49)

AGCTCCGGTGGTCCAGACACAGCTT[T/C]GTGGAGGAGGCCTGGGAGC

TGGGCTA

rs9331908:

(SEQ ID NO: 50)

GTGGACACAGGGCTCTGCCATCCCA[T/C]GAAGCAGTTTATTATGTCA

TCCAGCT

rs10779335:

(SEQ ID NO: 51)

GTGGCAGAAAGAAAGATCATGATCCT[C/T]GTTAGACTTAAAGGTCAG

GGATGTA

rs10779336:

(SEQ ID NO: 52)

TCCTCGTTAGACTTAAAGGTCAGGGA[G/T]GTAAACCTCCCAAACATC

TATGTAA

rs10863336:

(SEQ ID NO: 53)

GTTACTACAACTGAAGGACGGAAGGG[C/T]TTCCAGCCTCTAGTAGGT

AGAGGCC

rs10863417:

(SEQ ID NO: 54)

AGTGAGCCAAGACTGTGCCATTGCAC[A/T]CCAGCCTGGGTGACAGAG

TGAGACT

rs10863418:

(SEQ ID NO: 55)

CTAATTTTCTGTATCTATATCAGTCT[C/G]TAGTTAAAACCACACAGG

GGAAATG

rs10863420:

(SEQ ID NO: 56)

GAAGGAAGCCATGTGGGAAACACAGA[A/C]TATGAGTGGAGAGTATCG

TAGTGGT

rs11576522:

(SEQ ID NO: 57)

ATTTGGGTATCTCTTCCTAAATTCAT[A/G]TCAAACTAGAAGCATCAA

TTGCTTT

rs11579070:

(SEQ ID NO: 58)

CAGGACCAGTTGAGTCATGAGTCACA[A/G]GTCCAGGTAGAGTCAGTC

AGTTGCC

rs11803366:

(SEQ ID NO: 59)

TGTTTTCTTTTCCATGCTAAATTAAC[-/C/T]TCTGATGAATAGAGAC

AATTTTTTA

rs11803956:

(SEQ ID NO: 60)

TAACTCTTCAAGCTTCCATTCTAAAA[C/T]CCCTAATACCAACTCATA

CATAAAA

rs12028134:

(SEQ ID NO: 61)

GAAAAACATAAATAAATAAATTAAAT[A/T]AAATAAAACAAGAAAAGA

AACTAAA

rs12031281:

(SEQ ID NO: 62)

ATCCCTGCACTTTGGGAGGCTGAGGC[A/G]GGTGGGTCACCTGAGGTC

AGGAGTT

rs12032780:

(SEQ ID NO: 63)

ACCAGCTACTCGGGAGGTTGAAGCAT[A/G]AGAATTGCTTGAACCCAG

GAGGCAG

rs12034383:

(SEQ ID NO: 64)

AAATTATGTCAGAAATAGTGAAATGT[A/G]TTAAGGCATGGACATCTG

CCTATAA

rs12036785:

(SEQ ID NO: 65)

AACATGGTACTCCTGTTCCCTCACAG[A/C]GTGACCCCAGTGGCTCCA

GGGCTAG

rs12037841:

(SEQ ID NO: 66)

TACTTTCTTTTTTTTTTTTGATACAA[G/T]GTCTTGCTTTGTTGCCCA

GGCTGGA

rs12038371:

(SEQ ID NO: 67)

CCAAGAGGAAGGTTCTTTAAAGAGCT[A/G]TGCTCAGGATGGTCTTTC

TGTTGTA

rs12041437:

(SEQ ID NO: 68)

CCTGTGAAATGGAGATAATAATAGTT[A/C]CTACCTTACTTAACATAG

TGCCTCA

rs1408077:

(SEQ ID NO: 69)

TATTGGATTATTATTGTCATTTCCA[C/A]TGTTTTGGGGTGATGACTC

TATAAGT

rs1408078:

(SEQ ID NO: 70)

TGACATGACCCCACCCCCACATTCC[T/C]AGTCTCTCTTATCCTGCTT

TATTTTT

rs17186848:

(SEQ ID NO: 71)

ACTATGAGAAATTTCTCACTGGCTAG[C/T]TCCCCTTTTAACCTGGGC

TTTCCAT

rs17258982:

(SEQ ID NO: 72)

TGATACTTCTTACCTTCTTGATTGTC[A/G]TTACCTTATACGTGATAT

CAAAACA

rs1752684:

(SEQ ID NO: 73)

AGCTCAAGACCAGCCTAGACAACATG[A/G]CAAAAACCCATCTCTACA

AAAAAGT

rs1830763:

(SEQ ID NO: 74)

CAAAGGCAAAACTCCATCTGAAAAA[C/A]ATAAATAAATAAATTAAAT

AAAATAA

rs2093760:

(SEQ ID NO: 75)

ACCAAATGGGAAGAGAGGTTCTCAA[G/A]CCAGTCCATGGATTTACCT

GGAACTT

rs2093761:

(SEQ ID NO: 76)

GTGGAGAAGAGTTTTATTGAGTGAC[G/A]AAACAGCTTCTCAGCGGAG

ACGAGAC

rs2182911:

(SEQ ID NO: 77)

AATTTTAAGACAGTGACAGTAGGATT[C/T]GTGGATAGTTTGTATCAG

AATATGA

rs2182912:

(SEQ ID NO: 78)

AAAATTTGGGCTTTGTCATCATGTGG[A/T]TGTACATAACAAGGAGAC

TGAATAA

rs2182913:

(SEQ ID NO: 79)

AACAAGGAGACTGAATAAGATCTCCG[A/G]GAAGTGAAAGAGGCTAGC

AAAAAGA

rs2274566:

(SEQ ID NO: 80)

ATTACCTGAATAACAATGGTACAAAT[C/T]GGGATTACCTTCCTAGGA

AATATGT

rs2296160:

(SEQ ID NO: 81)

TGTGACTTTTGTCTTCCTTTTAGGT[T/G/A]CACATGATGCTCTCTCA

TAGTTGGTAAG

rs3737002:

(SEQ ID NO: 82)

AGAGCAGTTTCCATTTGCCAGTCCTA[C/T]GATCCCAATTAATGACTT

TGAGTTT

rs3738469:

(SEQ ID NO: 83)

GGCGCTAAGACTCAATTTCACACTAC[A/G]CGCCCAGGCCACGCCCAC

CTGTCAT

rs3849266:

(SEQ ID NO: 84)

CTCGCCCCTCAATCTGCATTGATCCA[C/T]TCCTTAATTTACATGTAA

CCGAAAT

rs3886100:

(SEQ ID NO: 85)

AATTGGGGCTGGGCCTTAGATTGTGA[A/G]CTAAGTGTCCTCTTGGCT

GAAACAG

rs4266886:

(SEQ ID NO: 86)

TTTATGTGGAAAAAGAATCAGATGAA[C/T]GGCATATATGGCAAGATC

TCACTTT

rs4274065:

(SEQ ID NO: 87)

CAGTGTCCACATGTATAAAATGAGCA[-/C/T]AACTGACATCCTGATC

TCTGAGAGA

rs4310446:

(SEQ ID NO: 88)

GCGGTTTGCCTAAGACCTCATAGCCA[-/C/T]TAAGTAGAAGACATTG

GGTTCAAGA

rs4525038:

(SEQ ID NO: 89)

CCTCAAGGTTCATTAATGTTGTAGCA[C/T]GTGTCAGAATTTCTTTCC

TTTTTAA

rs4562624:

(SEQ ID NO: 90)

AAATGTTACTTTTACTAGAAAGTTTA[A/C]GAGCTTCAGAATCTAAGT

TTACAAA

rs4618970:

(SEQ ID NO: 91)

TGGCAAAGGTGGAATGCAAGCTCATG[C/T]CTGAGTTTAAACTGCTTT

CTCCTAC

rs4618971:

(SEQ ID NO: 92)

AGAAACCATAGTCTTCCAGAATCACA[C/T]TGAACTATGGGAAAGAGG

GGATTTC

rs4844383:

(SEQ ID NO: 93)

ATGCTGGGAAGTCCTGTGAAATGGAA[C/G]GAGAACGAAGATGAGGAA

TCTGGTG

rs4844597:

(SEQ ID NO: 94)

ATGCTGATGGATGCTTCCAGTGTGCA[-/A/C/T]GGTCCTTTGGAATT

TTAAAGAAGTA

rs4844600:

(SEQ ID NO: 95)

GCCAGGCCTACCAACCTAACTGATGA[A/C/G]TTTGAGTTTCCCATTG

GGACATATC

rs4844610:

(SEQ ID NO: 96)

CCCATTTCTACACAAAACAGCCTTGT[A/C]CACAGTCAAAATTTCAAA

GTTTCCA

rs6540433:

(SEQ ID NO: 97)

CTTATACGTGATATCAAAACACAGAG[A/C]ACGGTAAGTTCAAAGGCG

AATACTT

rs6661489:

(SEQ ID NO: 98)

CCACCGTGCCCGGCCTCTATGTTTTA[C/T]AGAGAATATGTGCCTTAG

ACACATC

rs6661764:

(SEQ ID NO: 99)

TAATGTCTCCATTTTCGCCATACTTT[A/C/G]TATGTCCTACATAGCA

GCCATCACA

rs6686325:

(SEQ ID NO: 100)

TTCTATGCTCACAGTGTAAACAAAGC[A/G]CCAGGGAAGCCTGAACTG

GGTGGAG

rs6690215:

(SEQ ID NO: 101)

TTTGGTGAGGATGCAAAGCAAATGGT[C/T]AATATTTGGGAGTTTTAA

TCAGGAA

rs6697005:

(SEQ ID NO: 102)

AGTATTCTTAAGCTTCTTTGCATATT[-/A/G]TTAGACATTTGCATAT

ACACCTTGA

rs6701713:

(SEQ ID NO: 103)

TGATAATGCCTGCAGCCCAACAGATG[A/G]CAGTGTGCTTAACAGCTC

TGTCAAT

rs679515:

(SEQ ID NO: 104)

GCTGAGATCACGCCACTGCACTCCAG[C/T]GTGGGGAACAGAGTGAGG

ATCTGTT

rs7515905:

(SEQ ID NO: 105)

CACCAGAATCACTTGAACCTGGGAGG[C/T]GGAGTTTGCAGTGAGCCG

AGATGGC

rs7519119:

(SEQ ID NO: 106)

AGGAATGGGCTCTGAGCAGTGCTGGC[A/G]GCTGGACCAGGCATGTCG

CACTGAA

rs7519408:

(SEQ ID NO: 107)

CAGTGAATAGAAAGCAAATTATTCAG[C/G]TGAGAGTGAGGCTCAGAA

AGGAGGT

rs7525160:

(SEQ ID NO: 108)

AAGGTTTAAAGTCAAAATTATTTTAA[C/G]AGAAAAACCCAGGCAAAA

TAGCCTA

rs7525170:

(SEQ ID NO: 109)

ACCCAGGCAAAATAGCCTACCTACAG[A/G]CAGGCAGTACATGTCAGA

AGGACAG

rs7533520:

(SEQ ID NO: 110)

GATAACAATACATACCCACTAGAATG[-/A/G]CTAAAATGAAAAAGAT

TGACCGAGG

rs7542544:

(SEQ ID NO: 111)

AACAGGGGTGCCCATGACCCCAAAGC[A/C]CAGAGGAGGTGTTACAGC

ACACTAA

rs9429779:

(SEQ ID NO: 112)

ATGGAGGAAGGCAAAGGGGAAGCAAG[A/G]CATCTCATACGGTGGGAG

CAGGAGG

rs9429780:

(SEQ ID NO: 113)

AGCCACATTCAGTTTCACAGGTATGA[C/G]AGCAAAATAATGGAGAAT

TGATTCT

rs9429781:

(SEQ ID NO: 114)

AATAATGGAGAATTGATTCTAACCAG[G/T]AATGTTGTTTTGTCTAAT

GGCTATA

rs9429784:

(SEQ ID NO: 115)

TCTCCACATGCCAGTGATTTCTGTTC[A/G]TTTTTCTTTATCTCCAGT

GAAATCC

rs9429940:

(SEQ ID NO: 116)

GAAGCATTTTCTGGGGTTATGATGGC[C/T]TTACCTTTATTAGGAAGT

ATGGTTT

rs9429941:

(SEQ ID NO: 117)

CAGTGGGTGCAAGATGGTGATTATAA[A/T]GACAGAGTATGGAATTTA

ACCTGGT

rs9429942:

(SEQ ID NO: 118)

CACAACGTGCAGGTTTGTTACATATG[C/T]ATACATGTGCGACGTTGG

TGTGCTG

rs9429945:

(SEQ ID NO: 119)

ATGTATTCTCTTCCAGTTCTGGAGGC[-/C/T]GACGTCTAAAATAGAT

CCATAGGGC

Preferably also, in the above-defined method, it is deduced that the individual is at risk of developing Alzheimer's disease as defined above if said individual is homozygous for the at least one variant allele or for the at least one variation.

As intended herein the expression “homozygous” means that the at least one variant allele or the at least one variation is present for the two genomic copies of the gene.

As intended herein, the expression “risk factor for Alzheimer's disease” relates to all characteristics of an individual, in particular of a genetic, environmental, or physiological nature, which are known to be predictive of Alzheimer's disease as defined above. Numerous risk factors for Alzheimer's disease are known in the art.

However, it preferred within the frame of the present invention that the at least one other risk factor for Alzheimer's disease is a variant allele of the apolipoprotein E gene.

Variant alleles of the apolipoprotein E gene constituting a risk factor for Alzheimer's disease as defined above are well known to one of skill in the art and notably encompass the ε4 allele of APOE, in particular as described by Farrer et al. (Farrer et al. (1997) JAMA 278:1349-1356.).

Example 1
Methods
AD Samples

All AD cases were ascertained by neurologists from Bordeaux, Dijon, Lille, Montpellier, Paris, Rouen, and were identified as French Caucasian. Clinical diagnosis of probable AD was established according to the DSM-III-R and NINCDS-ADRDA criteria (McKhann et al. (1984) Neurology 34:939-944). Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian, or other proxy, and the study protocols for all populations were reviewed and approved by the appropriate Institutional review boards. Genomic DNA samples from 2,344 AD cases were available for analysis prior to genotype quality control steps.

Control Samples

Controls were selected from the 3C Study (Alpérovitch et al. (2003) Neuroepidemiology 22:316-325). This cohort is a population-based, prospective (4-years follow-up) study of the relationship between vascular factors and dementia. It has been carried out in three French cities: Bordeaux (southwest France), Montpellier (southeast France) and Dijon (central eastern France). A sample of non-institutionalised, over-65 subjects was randomly selected from the electoral rolls of each city. Between January 1999 and March 2001, 9,686 subjects meeting the inclusion criteria agreed to participate. Following recruitment, 392 subjects withdrew from the study. Thus, 9,294 subjects were finally included in the study (2,104 in Bordeaux, 4,931 in Dijon and 2,259 in Montpellier). At 4 years of follow-up, three hundred and fifty individuals were demented, with 143 prevalent cases (91 cases of AD, 39 cases of mixed/vascular dementia, 3 cases of Parkinsonian dementia and 10 cases of other types of dementia) and 207 incident cases (135 cases of AD, 40 cases of mixed/vascular dementia, 15 cases of Parkinsonian dementia and 17 cases of other types of dementia). Prevalent and incident AD cases were included as cases. Patients with other types of dementia, and individuals for whom information on their dementia status during the 4-year follow-up was missing were excluded (n=854; refusal or lost to follow-up and death). At this stage, genomic DNA samples of 7,076 controls were available from the 3C study prior to genotype quality control steps. Supplementary control data on additional anonymised samples were used in some analyses as explained in the text below (Heath et al. (2009) Eur. J. Hum. Genet. 16:1413-29).

Genotyping

DNA samples were transferred to the French Centre National de Génotypage (CNG) for genotyping. First stage samples that passed DNA quality control were genotyped with Illumina Human 610-Quad BeadChips. Genotype data were retained in the study for samples that had been successfully genotyped for >98% of the SNP markers. SNPs with call rate <98%, with minor allele frequency (MAF)<1% or exhibiting departure from the Hardy-Weinberg equilibrium in the control population (p<10−6) were excluded. 134 AD cases and 980 controls samples were removed because they were found to be first- or second-degree relatives of other study participations, or were assessed non-Caucasian based on genetic analysis using methods described in Heath et al. (2009) Eur. J. Hum. Genet. 16:1413-29. 537,029 autosomal SNPs genotyped in 2,032 cases and 5,328 controls were thus retained. In order to avoid any genotyping bias, cases and controls were randomly mixed when genotyping, and laboratory personnel were blinded to case/control status. Genotyping success rate was at least 95%, and no departure from Hardy-Weinberg equilibrium was observed for the markers included in the second stage.

Statistical Analysis

The case and control differences were evaluated using a logistic regression, which optionally incorporated principal components that were significantly associated with disease status to account for possible population stratification as described in Heath et al. (2009) Eur. J. Hum. Genet. 16:1413-29 and Price et al. (2006) Nat. Genet. 38:904-909. It was hypothesized that the relatively high genomic control without the adjustment with principal components was due to differences in representation of various French regions in the case and control series. Therefore, the robustness of the conclusions were further explored through incorporation of 6,734 anonymised samples from France and other European countries as additional controls (Heath et al. (2009) Eur. J. Hum. Genet. 16:1413-29). With the inclusion of the additional samples, the genomic control parameter was 1.04 without adjustment with principal components, and 1.03 after adjustment. The inclusion of the additional controls did not substantially modify the association statistics for markers in regions showing suggestive evidence of association (p<10−5) after correction for population structure in the primary analysis. Statistical analyses were undertaken under an additive genetic model using logistic regression taking account of age, sex and disease status using SAS software release 9.1 (SAS Institute, Cary, N.C.). Population controls that were not genotyped specifically for this study were excluded, as were any samples with missing age or gender data. This gave a maximum of 2,025 AD cases and 5,328 controls. Information on age and gender in the cases and controls included in these analyses are shown in Table 1.

TABLE 1

population characteristics

AD cases
Controls

n
2025
5328

Mean age
73.7 ± 8.9

Mean age at onset
68.3 ± 9.0
—

% male
34
39

Interactions between APOJ or CR1 SNPs and APOE ε4 polymorphism were tested in logistic regression models adjusted for age, gender and centres. The solid spine haplotype block definition in Haploview 4.0 was used to generate linkage disequilibrium blocks of the genomic regions encompassing the APOJ or CR1 genes from imputed SNPs (MAF>5%) (Barrett et al. (2005) Bioinformatics 21:263-5). Associations of the APOJ and CR1 haplotypes were estimated using logistic regression or proportional hazards models using Thesias 3.0 which implements a maximum likelihood model and uses a SEM algorithm (Tregouet & Tiret (2004) Eur. J. Hum. Genet. 12:971-974). The population attributable risk fraction was estimated using the formula: PAR=F(OR-1)/(F(OR-1)+1) where F is the frequency of the deleterious allele in the sample and OR the odds ratio of AD risk associated to the deleterious allele.

URLs

Haploview: http://www.broad.mit.edu/mpg/haploview/index.php

Revman: http://www.cc-ims.net/revman/

Thesias: http://ecgene.net/genecanvas/uploads/THESIAS3.1/

HapMap: http://www.hapmap.org

Results
Study of Late-Onset AD

A genome-wide association (GWA) analysis of 537,029 SNPs in 2,032 French AD cases and 5,328 French controls was undertaken. Patients with probable AD according to DSM-III-R and NINCDS-ADRDA criteria were ascertained by neurologists. Individuals without symptoms of dementia from French Three-City (3C) prospective population-based cohort (described in Methods) were obtained as controls. The study samples were genotyped with Illumina Human 610-Quad BeadChip, and subjected to standard quality controls procedures (see Methods).

The resulting GWA data were then analyzed for association with a logistic regression taking into sex and age, and using principal components to adjust for possible population stratification as described (see Methods). Prior to adjustment for possible population stratification the genomic control parameter was 1.20, but after adjustment it became 1.04. The observed versus expected X²distribution (quantile-quantile plots) did not indicate substantial inflation of the test statistics after adjustment. Additional tests were undertaken to establish the robustness of the statistical results as described in the Methods.

Several APOE-linked SNPs gave strong evidence of disease association (Table 2).

TABLE 2

Association statistics from the GWA at the APOE locus.

Frequency (Reference allele)

supp.

rs
Chr
Pos (bp)
cases
controls
controls
Analysis 1
Analysis 2
Analysis 3

2965109
19
49917185
—
—
—
1.70E−09
1.60E−07
—

7254776
19
49919582
—
—
—
2.80E−09
1.50E−07
—

2927488
19
49923318
0.764
0.723
0.741
5.06E−07
5.42E−06
1.78E−05

2965101
19
49929652
0.691
0.634
0.653
6.87E−11
3.84E−09
8.54E−10

17728272
19
49932211
—
—
—
2.70E−07
3.10E−06
—

8100239
19
49944944
—
—
—
2.00E−09
3.60E−08
—

8103315
19
49946008
—
—
—
5.70E−07
5.10E−06
—

4803759
19
50019299
—
—
—
5.10E−07
2.20E−06
—

10402271
19
50021054
0.626
0.696
0.695
6.44E−16
1.90E−14
<2e−16

7408909
19
50023565
—
—
—
1.30E−14
7.90E−14
—

7359852
19
50027875
—
—
—
<2e−16
<2e−16
—

2927480
19
50029225
—
—
—
<2e−16
<2e−16
—

1871047
19
50043586
0.64
0.597
0.591
1.59E−06
9.41E−07
1.10E−07

1871046
19
50043777
—
—
—
1.60E−06
6.80E−07
—

4803763
19
50049131
—
—
—
<2e−16
<2e−16
—

440277
19
50053064
—
—
—
8.80E−11
2.60E−09
—

12978931
19
50055540
—
—
—
7.80E−06
5.20E−06
—

6859
19
50073874
0.49
0.42
0.424
1.07E−13
1.01E−12
4.95E−15

11669338
19
50074824
—
—
—
1.70E−11
1.20E−09
—

11673139
19
50074877
—
—
—
1.70E−11
1.20E−09
—

3852861
19
50074901
—
—
—
9.50E−06
9.50E−06
—

3745150
19
50077599
—
—
—
<2e−16
<2e−16
—

283813
19
50081014
—
—
—
2.90E−07
7.20E−07
—

6857
19
50084094
—
—
—
<2e−16
<2e−16
—

157580
19
50087106
0.288
0.402
0.412
<2e−16
<2e−16
<2e−16

2075650
19
50087459
0.727
0.899
0.884
<2e−16
<2e−16
<2e−16

157583
19
50088513
—
—
—
4.40E−08
7.20E−06
—

8106922
19
50093506
0.672
0.57
0.598
<2e−16
<2e−16
<2e−16

10119
19
50098513
—
—
—
<2e−16
<2e−16
—

405509
19
50100676
0.542
0.458
0.479
<2e−16
<2e−16
<2e−16

439401
19
50106291
0.28
0.391
0.391
<2e−16
<2e−16
<2e−16

4420638
19
50114786
—
—
—
<2e−16
<2e−16
—

4803770
19
50119193
—
—
—
2.40E−16
2.60E−15
—

5112
19
50122120
—
—
—
1.40E−08
9.40E−07
—

12721108
19
50139081
—
—
—
1.10E−07
2.80E−06
—

Markers are shown when p < 10⁻⁵in analysis 1.

Analysis 1 = GWA cases vs. study controls, logistic regression (age, gender adjusted);

Analysis 2 = GWA cases vs. study controls, logistic regression with principal components adjustment;

Analysis 3 = GWA cases vs. study and supplementary controls, logistic regression and principal components adjustment.

Outside of APOE, one marker, rs11136000, within the apolipoprotein J gene (APOJ) on chromosome 8p21-p12 gave P=9.0×10⁻⁸in the association test. This slightly surpassed the criteria for genome-wide significance as evaluated with a conservative Bonferroni correction (P<9.3×10⁻⁸). Markers in several chromosome regions were observed with suggestive evidence of association (P<10⁻⁵) as shown in Table 3. Finally, imputation of genotypes using the HapMap CEU samples to increase the number of SNPs examined in these regions was undertaken. The genotyped and imputed markers from the regions that gave P<10⁻⁵in the original case/control comparison are shown in Table 3.

TABLE 3

Results from the GWA for regions containing markers with p < 10⁻⁵in analysis 1.

Frequency (Reference allele)

supp.

rs
Chr
Pos (bp)
cases
controls
controls
Analysis 1
Analysis 2
Analysis 3

2182912
1
205726967
—
—
—
5.30E−05
6.19E−05
—

4844597
1
205737892
—
—
—
4.70E−05
5.79E−05
—

4274065
1
205738099
—
—
—
4.70E−05
5.90E−05
—

9429945
1
205743391
—
—
—
8.99E−05
1.70E−04
—

6656401
1
205758672
—
—
—
6.40E−05
1.10E−04
—

3818361
1
205851591
0.217
0.179
0.199
2.35E−07
2.87E−06
5.96E−06

6701713
1
205852912
0.217
0.179
0.2
2.40E−07
2.89E−06
6.39E−06

2296160
1
205861943
—
—
—
2.90E−07
3.40E−06
—

1408078
1
205867178
—
—
—
2.90E−07
3.40E−06
—

4844610
1
205869175
—
—
—
8.89E−07
9.29E−06
—

1408077
1
205870764
0.212
0.176
0.198
3.68E−07
4.72E−06
9.05E−06

11952762
5
118383450
0.953
0.93
0.945
3.64E−07
6.62E−06
0.000144

11959554
5
118399338
—
—
—
3.30E−06
4.60E−05
—

12201301
6
31115536
0.969
0.982
0.974
1.46E−06
3.88E−06
4.96E−05

11768400
7
84893471
—
—
—
3.10E−05
7.00E−07
—

6465004
7
84894842
—
—
—
3.10E−05
7.10E−07
—

11762648
7
84915141
—
—
—
5.30E−05
1.70E−06
—

12704129
7
84917284
—
—
—
2.70E−05
7.91E−07
—

11769386
7
84921805
—
—
—
2.90E−05
8.20E−07
—

2462051
7
84937706
—
—
—
6.90E−04
1.20E−05
—

2462049
7
84937834
—
—
—
5.00E−04
1.10E−05
—

2463670
7
84942229
—
—
—
3.30E−06
1.80E−07
—

13231722
7
84953822
—
—
—
6.00E−04
2.40E−05
—

10499889
7
84959000
0.535
0.572
0.55
5.20E−05
4.54E−06
0.000305

6951823
7
84998691
—
—
—
3.10E−04
1.10E−05
—

10252600
7
85015874
—
—
—
3.70E−04
1.30E−05
—

12334143
7
85020952
—
—
—
8.00E−06
8.00E−07
—

12333397
7
85020998
—
—
—
1.40E−05
1.80E−06
—

3087554
8
27511359
—
—
—
1.00E−04
2.80E−04
—

2279590
8
27512170
—
—
—
5.00E−06
4.90E−07
—

11136000
8
27520436
0.346
0.389
0.379
1.32E−06
8.99E−08
1.94E−08

9331888
8
27524779
—
—
—
1.20E−06
3.10E−06
—

12931878
16
10949695
—
—
—
1.10E−05
1.70E−04
—

8055533
16
10949740
0.652
0.693
0.679
1.70E−06
1.25E−06
7.06E−06

4781028
16
10966864
—
—
—
8.59E−06
1.30E−04
—

9302457
16
10967338
—
—
—
7.50E−07
2.20E−06
—

16957843
16
10968706
—
—
—
9.71E−05
4.30E−04
—

16957849
16
10972808
—
—
—
7.40E−06
1.20E−04
—

All markers with p < 10−4 in analysis 1 are shown for these regions.

Markers with allele frequencies absent and no results for analysis 3 have been imputed.

Analysis 1 = GWA cases vs. study controls, logistic regression (age, gender adjusted);

Analysis 2 = GWA cases vs. study controls, logistic regression with principal components adjustment;

Analysis 3 = GWA cases vs. study and supplementary controls, logistic regression and principal components adjustment.

APOJ

At APOJ on 8p21-p12, four SNPs (rs3087554, rs2279590, rs11136000 and rs9331888) were tested that showed evidence of association and were not in complete LD. Three of these markers (rs2279590, rs11136000 and rs9331888) exhibited statistically significant association with AD (Table 4). Strong evidence for association was found in the GWA datasets taking into account the sample origin in the logistic regression, with two markers exceeding the criterion for genome-wide significance (P<9.3×10⁻⁸). For the marker showing the strongest evidence of association (rs11136000), the odds ratio for the minor allele was 0.86 (95% Cl 0.81-0.90, P=7.5×10⁻⁹).

The effect of the APOJ locus taking into account APOE ε4 status in cases and controls was also examined (Table 4).

TABLE 4

Association of SNPs at the APOJ locus with AD.

N
MAF

Association test

Cases
Controls
Cases
Controls
HW
OR (95% CI)
P value

rs2279590
2025
5328
0.36
0.41
3 · 1 · 10⁻¹
0.83
1 · 0 · 10⁻⁶

(0.77-0.90)

rs11136000
2016
5266
0.35
0.39
6 · 0 · 10⁻¹
0.83
1 · 5 · 10⁻⁶

(0.77-0.90)

rs9331888
2025
5328
0.31
0.28
8 · 9 · 10⁻¹
1.19
1 · 8 · 10⁻⁵

(1.11-1.30)

P values and odds ratios (OR) with their 95% confidence interval (95% CI) have been calculated under an additive model using logistic regression models adjusted for age, gender and centres when necessary.

MAF = minor allele frequency;

HW = P value for the test of Hardy Weinberg Equilibrium in controls.

A statistical interaction between the APOE ε4 status and the APOJ SNPs (ranging from 3.0×10⁻²to 5.2×10⁻²according to the SNP tested) was detected. For rs11136000, while the association was significant in both ε4 carriers and non-carriers, it was greater in carriers (OR=0.81, P=2.7×10⁻⁵in carriers, OR=0.91 P=7.0×10⁻³in non-carriers). Analysis of the GWA data showed that these markers are within a LD block that encompasses only the APOJ gene. The three APOJ locus markers define three common haplotypes (frequency>2%) that together account for 98.2% of the observations in controls. Compared to the most frequent TTC haplotype, the other two frequent haplotypes were all associated with a statistically significant increased disease risk (Table 5). The odds ratio was highest for the CCG haplotype compared to the TTC haplotype, with the following AD risk and association p-values: OR=1.28, P=1.5×10⁻⁷.

TABLE 5

Haplotypes
Cases
Controls
OR (95% CI)
P values

TTC
0.344
0.388
Ref.
—

CCC
0.334
0.329
1.14 (1.04-1.24)
3.0.10⁻³

CCG
0.302
0.265
1.28 (1.17-1.41)
1.5.10⁻⁷

Association results for haplotypes at the APOJ locus. The results have been calculated using the Thesias programme with adjustment for age, gender and centre. The P value for the global association was 1.8.10⁻⁶. The markers as ordered from left to right (5′ to 3′) are rs2279590, rs11136000 and rs9331888. Minor alleles are underlined.

CR1

A second locus of potential interest lies within a LD block that encompasses CR1 on 1q32. Two SNPs were tested at this locus (rs6656401 and rs3818361) which showed evidence of association with disease (Table 6).

TABLE 6

Association of SNPs at the CR1 locus with AD.

N
MAF

Association test

Cases
Controls
Cases
Controls
HW
OR (95% CI)
P value

rs6654601
2025
5324
0.22
0.18
9 · 9 · 10⁻¹
1.27
1 · 8 · 10⁻⁷

(1.16-1.39)

Rs3818361
2018
5324
0.22
0.18
8 · 5 · 10⁻¹
1.28
8 · 5 · 10⁻⁸

(1.17-1.40)

P values and odds rations (OR) with their 95% confidence interval (95% CI) have been calculated under an additive model using logistic regression models adjusted for age, gender and centres when necessary.

MAF = minor allele frequency;

HW = P value for the test of Hardy Weinberg Equilibrium in controls.

At this locus, a statistical interaction with APOE ε4 status and risk of disease (P=9.6.10⁻³) was also detected with significant association in both carrier and non-carriers but stronger in the former. For rs6656401, OR=1.38 (95% Cl 1.22-1.55) in carriers, OR=1.13 (95% 1.04-1.23) in non-carriers was obtained. There was evidence association of the rs3818361 SNP in the APOE ε4 carriers (OR=1.38 95% Cl 1.19-1.60, P=2.3.10⁻⁵).

The genotyped markers define two principal haplotypes that account for 97.8% of the observations at the CR1 locus, while a third haplotype has an estimated frequency of 1.2% in the combined control population (Table 7). The odds ratio was highest for the AA haplotype compared to the GG haplotype, with the following AD risk and association p-values: OR=1.28, P=1.4×10⁻⁷.

TABLE 7

Haplotypes
Cases
Controls
OR (95% CI)
P values

GG
0.772
0.813
Ref.
—

GA
0.011
0.009
1.25 (0.87-1.80)
2.2.10⁻¹

AA

0.207
0.170
1.28 (1.17-1.40)
1.4.10⁻⁷

Association results for haplotypes at the CR1 locus. The results have been calculated using the Thesias programme with adjustment for age, gender and centre. The P value for the global association was 7.5.10⁻⁷. The markers as ordered from left to right (5′ to 3′) are rs6656401 and rs3818361. Minor alleles are underlined.

The attributable fraction of risk was calculated to be 25.5% for APOE, 8.9% for APOJ and 3.8% for CR1. If the estimate that 60-80% of the AD risk is due to genetic factors is correct, additional genetic susceptibility loci still remain to be identified. This situation is similar to that of many other diseases in which loci have been successfully mapped by GWA.

In summary, in addition to the previously known APOE locus, new loci at APOJ and CR1 have been identified that are potentially associated with the risk of late-onset AD.

Example 2

Applying the same approach as the one described in Example 1 on the 1000 genome project panel: pilot 1, CEU, the inventors identified other SNPs at the APOJ locus and at the CR1 locus that were associated with Alzheimer's disease. The SNPs at the APOJ locus are referenced in Table 8 and the SNPs at the CR1 locus are referenced in Table 9.

TABLE 8

Association of SNPs at the APOJ locus with AD.

rs
Chr
Pos (bp)
Allele
Strand
MAF
Rsq
OR [CI]
p-value

10091215
8
27507636
T
+
0.222059
0.7988
1.1
4.32E−02

[1.01; 1.19]

1073742
8
27536374
A
−
0.451584
0.9138
0.9
3.88E−03

[0.83; 0.97]

1073743
8
27536129
A
−
0.459537
0.9069
0.9
6.40E−03

[0.82; 0.98]

10780145
8
27490639
T
+
0.439375
0.8642
1.12
3.91E−03

[1.04; 1.2]

10866859
8
27490635
A
+
0.172597
0.9949
1.13
1.48E−02

[1.03; 1.23]

11136000
8
27520436
T
+
0.37561
0.9804
0.8
4.73E−08

[0.72; 0.88]

11318062
8
27533396
C
+
0.008581
0.2691
0.51
5.20E−03

[0.04; 0.98]

11787077
8
27521229
T
+
0.386424
0.8485
0.8
2.03E−08

[0.72; 0.88]

1532276
8
27522074
T
+
0.386424
0.8427
0.8
2.09E−08

[0.72; 0.88]

1532277
8
27522098
T
+
0.386424
0.8421
0.8
2.09E−08

[0.72; 0.88]

1532278
8
27522232
T
+
0.385238
0.82
0.8
1.47E−08

[0.72; 0.88]

17057419
8
27493305
G
+
0.172597
0.9968
1.13
1.48E−02

[1.03; 1.23]

17466684
8
27508764
A
+
0.131785
0.4109
1.17
5.06E−03

[1.06; 1.28]

1982229
8
27530518
T
+
0.374494
0.822
1.11
7.88E−03

[1.03; 1.19]

2070926
8
27523738
C
−
0.382238
0.702
0.79
8.57E−09

[0.71; 0.87]

2279590
8
27512170
T
−
0.386633
0.7866
0.81
1.48E−07

[0.73; 0.89]

2279591
8
27509680
T
−
0.233501
0.5168
1.17
6.19E−04

[1.08; 1.26]

2582367
8
27535944
C
+
0.461699
0.9201
0.91
1.05E−02

[0.83; 0.99]

28558661
8
27510265
G
+
0.24857
0.5194
1.14
2.90E−03

[1.05; 1.23]

35810222
8
27516103
C

0.373308
0.6737
1.24
8.25E−08

[1.16; 1.32]

4236673
8
27520846
A
+
0.379866
0.9365
0.8
4.12E−08

[0.72; 0.88]

4352801
8
27491118
C
+
0.426748
0.9877
1.1
1.16E−02

[1.02; 1.18]

4732728
8
27497438
G
+
0.416492
0.8116
1.1
1.18E−02

[1.02; 1.18]

4732729
8
27517409
A
+
0.398493
0.6849
1.24
7.45E−08

[1.16; 1.32]

4732732
8
27532345
A
+
0.490512
0.8735
1.09
1.96E−02

[1.01; 1.17]

484377
8
27533428
C
+
0.455281
0.8927
0.9
6.26E−03

[0.82; 0.98]

485902
8
27545878
C
−
0.448165
0.9449
0.91
1.02E−02

[0.83; 0.99]

492638
8
27535146
T
+
0.305846
0.9976
0.9
1.11E−02

[0.82; 0.98]

495150
8
27538273
G
+
0.307242
0.9961
0.9
1.08E−02

[0.82; 0.98]

504038
8
27531239
T
+
0.416981
0.8728
0.91
1.19E−02

[0.83; 0.99]

507341
8
27537903
C
+
0.330403
0.9693
0.89
5.23E−03

[0.81; 0.97]

518317
8
27535664
G
+
0.396819
0.7495
0.91
2.36E−02

[0.83; 0.99]

520186
8
27535022
A
+
0.457932
0.9214
0.91
1.21E−02

[0.83; 0.99]

536332
8
27531686
G
+
0.457653
0.8988
0.91
1.09E−02

[0.83; 0.99]

538181
8
27532734
G
+
0.455281
0.8899
0.9
6.26E−03

[0.82; 0.98]

569205
8
27532938
T
+
0.412237
0.8856
0.89
3.52E−03

[0.81; 0.97]

576748
8
27542835
A
+
0.325171
0.9068
0.9
1.07E−02

[0.82; 0.98]

6983452
8
27503945
T
+
0.432887
0.7783
1.13
1.89E−03

[1.05; 1.21]

7828131
8
27496927
C
+
0.39926
0.9966
1.09
2.31E−02

[1.01; 1.17]

7982
8
27518398
A
−
0.377145
0.9212
0.8
5.92E−08

[0.72; 0.88]

867230
8
27524420
C
+
0.37861
0.7045
0.79
1.28E−08

[0.71; 0.87]

9314349
8
27530121
G
+
0.381192
0.9749
1.1
1.86E−02

[1.02; 1.18]

9331896
8
27523603
C
−
0.382238
0.7027
0.79
8.57E−09

[0.71; 0.87]

9331908
8
27519535
T
−
0.366541
0.6772
1.24
6.32E−08

[1.16; 1.32]

8
27496798
A

0.0400446
0.334
0.77
1.01E−02

[0.57; 0.97]

8
27498182
T

0.173015
0.9923
1.12
2.18E−02

[1.02; 1.22]

8
27533395
T

0.008581
0.2688
0.51
5.20E−03

[0.04; 0.98]

8
27542063
G

0.0125576
0.4057
0.68
4.12E−02

[0.31; 1.05]

8
27542086
G

0.0347426
0.4618
0.74
6.89E−03

[0.52; 0.96]

8
27542087
A

0.0385098
0.4555
0.78
1.64E−02

[0.58; 0.98]

8
27542353
T

0.00634854
0.3569
0.54
2.47E−02

[0; 1.08]

TABLE 9

Association of SNPs at the CR1 locus with AD.

rs
Chr
Pos (bp)
Allele
Strand
MAF
Rsq
OR [CI]
p-value

10779335
1
205865317
C
+
0.185922
0.9938
1.25
3.96E−06

[1.16; 1.34]

10779336
1
205865339
T
+
0.187945
0.9251
1.24
5.01E−06

[1.15; 1.33]

10863336
1
205732543
T
+
0.290428
0.8185
0.87
1.50E−03

[0.79; 0.95]

10863417
1
205863520
A
+
0.185922
0.9928
1.25
3.96E−06

[1.16; 1.34]

10863418
1
205864861
C
+
0.18934
0.8956
1.26
9.74E−07

[1.17; 1.35]

10863420
1
205866497
A
+
0.185922
0.9942
1.25
3.96E−06

[1.16; 1.34]

11576522
1
205855892
A
+
0.379866
0.9842
1.14
6.18E−04

[1.06; 1.22]

11579070
1
205865764
A
+
0.388656
0.9483
1.13
1.77E−03

[1.05; 1.21]

11803366
1
205873612
T
+
0.400726
0.9197
1.13
1.24E−03

[1.05; 1.21]

11803956
1
205869644
T
+
0.400726
0.9575
1.13
1.23E−03

[1.05; 1.21]

12028134
1
205867032
A
+
0.403725
0.8918
1.12
2.50E−03

[1.04; 1.2]

12031281
1
205866777
A
+
0.271313
0.5949
0.91
3.04E−02

[0.82; 1]

12032780
1
205863461
G
+
0.400656
0.961
1.13
1.33E−03

[1.05; 1.21]

12034383
1
205870218
G
+
0.400726
0.9573
1.13
1.23E−03

[1.05; 1.21]

12036785
1
205859532
C
+
0.374913
0.9104
1.14
6.91E−04

[1.06; 1.22]

12037841
1
205750815
T
+
0.194642
0.6068
1.23
1.12E−05

[1.14; 1.32]

12038371
1
205887669
G
+
0.272708
0.8065
0.9
1.82E−02

[0.82; 0.98]

12041437
1
205869887
C
+
0.400726
0.9574
1.13
1.23E−03

[1.05; 1.21]

1408077
1
205870764
A
−
0.185922
0.996
1.25
3.96E−06

[1.16; 1.34]

1408078
1
205867178
T
−
0.220315
0.849
1.22
1.18E−05

[1.13; 1.31]

17186848
1
205871506
T
+
0.400795
0.9231
1.13
1.28E−03

[1.05; 1.21]

17258982
1
205719987
G
+
0.0743686
0.9565
1.22
4.52E−03

[1.08; 1.36]

1752684
1
205813919
A
+
0.379238
0.7949
1.15
2.98E−04

[1.07; 1.23]

1830763
1
205867012
C
−
0.185922
0.9947
1.25
3.96E−06

[1.16; 1.34]

2093760
1
205853451
A
−
0.198061
0.7983
1.22
2.51E−05

[1.13; 1.31]

2093761
1
205853165
A
−
0.218292
0.8
1.22
1.95E−05

[1.13; 1.31]

2182911
1
205726694
C
+
0.202386
0.9618
1.2
9.55E−05

[1.11; 1.29]

2182912
1
205726967
T
+
0.196735
0.9962
1.22
3.46E−05

[1.13; 1.31]

2182913
1
205727001
A
+
0.32245
0.9969
1.11
9.94E−03

[1.03; 1.19]

2274566
1
205819968
C
+
0.407841
0.8606
1.13
9.24E−04

[1.06; 1.2]

2296160
1
205861943
A
−
0.18927
0.9252
1.25
2.65E−06

[1.16; 1.34]

35659754
1
205891262
T
+
0.0115809
0.2587
0.68
4.45E−02

[0.3; 1.06]

3737002
1
205827396
T
+
0.277173
0.5634
0.91
2.32E−02

[0.82; 1]

3738469
1
205885045
A
+
0.0696247
0.9198
1.17
2.85E−02

[1.03; 1.31]

3818361
1
205851591
A
−
0.190038
0.9998
1.25
2.57E−06

[1.16; 1.34]

3849266
1
205819613
T
+
0.274173
0.5378
0.9
1.35E−02

[0.81; 0.99]

3886100
1
205805750
A
+
0.407632
0.6457
1.13
1.23E−03

[1.05; 1.21]

4266886
1
205752409
T
+
0.189968
0.6183
1.24
1.02E−05

[1.14; 1.34]

4274065
1
205738099
C
+
0.196596
0.9713
1.22
3.12E−05

[1.13; 1.31]

4310446
1
205743227
C
+
0.192549
0.9937
1.19
2.08E−04

[1.1; 1.28]

4525038
1
205730560
T
+
0.125087
0.9975
1.15
1.53E−02

[1.04; 1.26]

4562624
1
205752588
A
+
0.18648
0.6931
1.24
1.26E−05

[1.14; 1.34]

4618970
1
205728263
C
+
0.125087
1
1.15
1.53E−02

[1.04; 1.26]

4618971
1
205732684
C
+
0.244524
0.9516
1.17
3.34E−04

[1.08; 1.26]

4844383
1
205874544
C
+
0.258965
0.5906
0.9
2.07E−02

[0.81; 0.99]

4844597
1
205737892
C
+
0.196596
0.9715
1.22
3.12E−05

[1.13; 1.31]

4844600
1
205745930
A
+
0.179782
0.6831
1.24
1.59E−05

[1.14; 1.34]

4844610
1
205869175
A
+
0.185922
0.9954
1.25
3.96E−06

[1.16; 1.34]

6540433
1
205720018
C
+
0.168829
0.9886
1.2
3.20E−04

[1.1; 1.3]

6656401
1
205758672
A
+
0.18641
0.7022
1.24
1.20E−05

[1.15; 1.33]

6661489
1
205764667
T
+
0.189549
0.7203
1.24
1.21E−05

[1.15; 1.33]

6661764
1
205875008
G
+
0.276894
0.7135
0.9
1.58E−02

[0.82; 0.98]

6686325
1
205899980
A
+
0.268732
0.7374
0.92
4.36E−02

[0.84; 1]

6690215
1
205722673
C
+
0.438468
0.9994
1.12
2.66E−03

[1.04; 1.2]

6697005
1
205873353
G
+
0.185922
0.9387
1.25
3.96E−06

[1.16; 1.34]

6701713
1
205852912
A
+
0.190038
0.9998
1.25
2.57E−06

[1.16; 1.34]

679515
1
205817191
T
+
0.200014
0.6682
1.24
3.20E−06

[1.15; 1.33]

7515905
1
205804700
T
+
0.18927
0.7359
1.23
1.25E−05

[1.14; 1.32]

7519119
1
205852775
G
+
0.406376
0.9916
1.13
1.63E−03

[1.05; 1.21]

7519408
1
205727912
G
+
0.125017
0.9996
1.15
1.45E−02

[1.04; 1.26]

7525160
1
205735037
C
+
0.290638
0.8059
0.88
2.77E−03

[0.8; 0.96]

7525170
1
205735070
G
+
0.196735
0.9813
1.22
2.83E−05

[1.13; 1.31]

7533520
1
205740568
A
+
0.196944
0.9521
1.22
2.74E−05

[1.13; 1.31]

7542544
1
205852846
C
+
0.406376
0.9915
1.13
1.63E−03

[1.05; 1.21]

9429779
1
205731344
G
+
0.30466
0.9696
1.13
3.30E−03

[1.05; 1.21]

9429780
1
205733813
G
+
0.217315
0.9145
1.17
6.18E−04

[1.08; 1.26]

9429781
1
205733845
G
+
0.217315
0.9144
1.17
6.18E−04

[1.08; 1.26]

9429784
1
205766383
G

0.189828
0.7048
1.24
1.03E−05

[1.15; 1.33]

9429940
1
205729535
T
+
0.125087
1
1.15
1.53E−02

[1.04; 1.26]

9429941
1
205733926
T
+
0.245151
0.8949
1.17
4.03E−04

[1.08; 1.26]

9429942
1
205735253
C
+
0.327752
0.8495
1.1
1.86E−02

[1.02; 1.18]

9429945
1
205743391
T
+
0.192898
0.8999
1.19
2.58E−04

[1.1; 1.28]

1
205717682
C

0.0104646
0.5224
0.65
3.19E−02

[0.25; 1.05]

1
205734924
T

0.0232315
0.3693
0.7
9.86E−03

[0.43; 0.97]

1
205762211
G

0.00690666
0.5665
0.58
3.17E−02

[0.08; 1.08]

1
205796833
G

0.280243
0.5951
1.18
1.06E−04

[1.1; 1.26]

1
205857663
T

0.468746
0.6578
1.11
6.36E−03

[1.03; 1.19]

1
205862688
G

0.373029
0.9739
1.14
5.91E−04

[1.06; 1.22]

1
205867485
T

0.287847
0.6527
0.91
2.48E−02

[0.83; 0.99]

1
205877247
A

0.0618808
0.6939
1.18
3.19E−02

[1.03; 1.33]

1
205878796
T

0.0655783
0.7041
1.17
4.56E−02

[1.02; 1.32]

1
205879028
T

0.0658574
0.7997
1.17
3.64E−02

[1.02; 1.32]

1
205886998
A

0.0663458
0.9673
1.18
3.18E−02

[1.03; 1.33]

1
205888190
A

0.0242082
0.1925
1.35
1.16E−02

[1.12; 1.58]

1
205892038
G

0.0657179
0.9307
1.17
3.81E−02

[1.02; 1.32]

1
205895594
T

0.0076043
0.5694
0.54
1.40E−02

[0.04; 1.04]

METHOD FOR DETERMINING THE RISK OF OCCURRENCE OF ALZHEIMER'S DISEASE

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)

PCT Information